APA (7th ed.) Citation

Vijay Patil, P., Vanita Noronha, P., Sachin Babanrao Dhumal, B., Amit Joshi, P., Nandini Menon, D., Atanu Bhattacharjee, P., . . . Kumar Prabhash, P. (2020). Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: An open-label, parallel-group, non-inferiority, randomised, phase 3 trial. Elsevier.

Chicago Style (17th ed.) Citation

Vijay Patil, ProfDM, et al. Low-cost Oral Metronomic Chemotherapy Versus Intravenous Cisplatin in Patients with Recurrent, Metastatic, Inoperable Head and Neck Carcinoma: An Open-label, Parallel-group, Non-inferiority, Randomised, Phase 3 Trial. Elsevier, 2020.

MLA (9th ed.) Citation

Vijay Patil, ProfDM, et al. Low-cost Oral Metronomic Chemotherapy Versus Intravenous Cisplatin in Patients with Recurrent, Metastatic, Inoperable Head and Neck Carcinoma: An Open-label, Parallel-group, Non-inferiority, Randomised, Phase 3 Trial. Elsevier, 2020.